A number of other research analysts have also recently issued reports on NTLA. Zacks Investment Research raised shares of Intellia Therapeutics from a sell rating to a hold rating in a report on Wednesday, October 4th. Cann reaffirmed a hold rating on shares of Intellia Therapeutics in a report on Tuesday, August 1st. Chardan Capital reaffirmed a buy rating and issued a $20.00 target price (up from $19.00) on shares of Intellia Therapeutics in a report on Wednesday, August 2nd. Jefferies Group LLC reaffirmed a buy rating and issued a $36.00 target price on shares of Intellia Therapeutics in a report on Tuesday, October 3rd. Finally, Wedbush reaffirmed an ourperform rating and issued a $25.00 target price (down from $29.00) on shares of Intellia Therapeutics in a report on Wednesday, September 27th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. The stock has an average rating of Hold and a consensus target price of $30.17.
Shares of Intellia Therapeutics (NASDAQ NTLA) traded down $1.25 during trading hours on Friday, reaching $21.31. 813,160 shares of the company were exchanged, compared to its average volume of 331,782. Intellia Therapeutics has a 1 year low of $10.83 and a 1 year high of $33.34.
TRADEMARK VIOLATION WARNING: “Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock Rating Reaffirmed by Barclays PLC” was originally reported by BBNS and is owned by of BBNS. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://baseballnewssource.com/markets/intellia-therapeutics-inc-ntla-earns-buy-rating-from-barclays-plc/1760258.html.
Several institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its stake in shares of Intellia Therapeutics by 10.2% during the 2nd quarter. Vanguard Group Inc. now owns 997,288 shares of the company’s stock worth $15,957,000 after purchasing an additional 92,580 shares in the last quarter. GMT Capital Corp purchased a new position in shares of Intellia Therapeutics during the 3rd quarter worth approximately $8,214,000. Granahan Investment Management Inc. MA increased its stake in shares of Intellia Therapeutics by 7.0% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 286,144 shares of the company’s stock worth $7,111,000 after purchasing an additional 18,784 shares in the last quarter. Ark Investment Management LLC increased its stake in shares of Intellia Therapeutics by 118.9% during the 2nd quarter. Ark Investment Management LLC now owns 174,810 shares of the company’s stock worth $2,797,000 after purchasing an additional 94,960 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Intellia Therapeutics by 52.0% during the 2nd quarter. State Street Corp now owns 164,798 shares of the company’s stock worth $2,638,000 after purchasing an additional 56,363 shares in the last quarter. 48.89% of the stock is owned by institutional investors and hedge funds.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with our FREE daily email newsletter.